Health care professionals celebrate 'milestone' FDA approval for HER2-positive solid tumors

An analysis of global online conversations among health care professionals on social media in April revealed tremendous enthusiasm about FDA approval of a treatment for adults with advanced HER2-positive solid tumors. The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) — a HER2-directed antibody-drug conjugate previously approved

Related Keywords

Florida , United States , Davidr Gandara , David Cooke , Davis Healthdescribing , Sarah Sammons , Joaquim Bellmunt , Daiichi Sankyo , Marka Lewis , Vivek Subbiah , Lank Center , Sarah Cannon Research Institute , Dana Farber Cancer Institute , Genitourinary Oncology At Dana Farber Cancer Institute , Genentech , Twitter , Uc Davis Health , American College Of Cardiology , Astrazeneca , Genitourinary Oncology , Mayo Clinic , Bacillus Calmette Guerin , Intermountain Healthcare , American College ,